| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 866- | Lae, | Amygdalin from Apricot Kernels Induces Apoptosis and Causes Cell Cycle Arrest in Cancer Cells: An Updated Review |
| - | Review, | Var, | NA |
| 860- | Lae, | Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery |
| - | Review, | Var, | NA |
| 862- | Lae, | Molecular mechanism of amygdalin action in vitro: review of the latest research |
| - | Review, | Var, | NA |
| 8152- | lamb, | TRAIL/rTRAIL, | Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-κB and Activation of Caspases and Death Receptor 4 |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | SK-HEP-1 |
| 8148- | lamb, | Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells |
| - | in-vitro, | Pca, | LNCaP |
| 8156- | lamb, | A review on chemistry, source and therapeutic potential of lambertianic acid |
| - | Review, | Var, | NA |
| 2351- | lamb, | Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 8161- | LapC, | Lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells |
| - | in-vitro, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE450 | - | in-vitro, | ESCC, | KYSE-510 |
| 8175- | Las, | Lasiodin Inhibits Proliferation of Human Nasopharyngeal Carcinoma Cells by Simultaneous Modulation of the Apaf-1/Caspase, AKT/MAPK and COX-2/NF-κB Signaling Pathways |
| - | in-vitro, | NPC, | NA |
| 8249- | LCA, | Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells |
| - | in-vitro, | NSCLC, | NA |
| 8237- | LCA, | Role of Licochalcone A in Potential Pharmacological Therapy: A Review |
| - | Review, | Var, | NA |
| 8248- | LCA, | Licochalcone A Inhibits the Proliferation of Human Lung Cancer Cell Lines A549 and H460 by Inducing G2/M Cell Cycle Arrest and ER Stress |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H460 |
| 8245- | LCA, | Licochalcone A Upregulates Nrf2 Antioxidant Pathway and Thereby Alleviates Acetaminophen-Induced Hepatotoxicity |
| - | in-vivo, | LiverDam, | NA |
| 8244- | LCA, | Licochalcone A from licorice root, an inhibitor of human hepatoma cell growth via induction of cell apoptosis and cell cycle arrest |
| - | in-vitro, | Liver, | HepG2 |
| 8243- | LCA, | Licochalcone A Inhibits Cellular Motility by Suppressing E-cadherin and MAPK Signaling in Breast Cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
| 8241- | LCA, | Licochalcone A induces apoptotic cell death via JNK/p38 activation in human nasopharyngeal carcinoma cells |
| - | in-vitro, | NPC, | NA |
| 8261- | LCA, | Licochalcone A induces T24 bladder cancer cell apoptosis by increasing intracellular calcium levels |
| - | in-vitro, | CRC, | T24/HTB-9 |
| 8208- | LCA, | Licochalcone A inhibits PI3K/Akt/mTOR signaling pathway activation and promotes autophagy in breast cancer cells |
| - | in-vitro, | BC, | MCF7 |
| 8206- | LCA, | Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways |
| - | in-vivo, | GC, | BGC-823 |
| 8235- | LCA, | Anticancer effects of licochalcones: A review of the mechanisms |
| - | Review, | Var, | NA |
| 8210- | LCA, | Licochalcone A-Induced Human Bladder Cancer T24 Cells Apoptosis Triggered by Mitochondria Dysfunction and Endoplasmic Reticulum Stress |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 8233- | LCA, | Licochalcone A induces cell cycle arrest and apoptosis via suppressing MAPK signaling pathway and the expression of FBXO5 in lung squamous cell cancer |
| - | in-vitro, | Lung, | NA |
| 8232- | LCA, | Licochalcone A induces G2/M phase arrest and apoptosis via regulating p53 pathways in esophageal cancer: In-vitro and in-vivo study |
| - | vitro+vivo, | ESCC, | NA |
| 8341- | LDN, | Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy |
| - | Review, | Var, | NA |
| 8337- | LDN, | Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway |
| - | in-vitro, | CRC, | NA |
| 8287- | LE, | New insights into the antioxidant and apoptotic potential of Glycyrrhiza glabra L. during hydrogen peroxide mediated oxidative stress: An in vitro and in silico evaluation |
| - | in-vitro, | Nor, | NA |
| 8236- | LE, | Licorice (Glycyrrhiza glabra L.)-Derived Phytochemicals Target Multiple Signaling Pathways to Confer Oncopreventive and Oncotherapeutic Effects |
| - | Review, | Var, | NA |
| 8265- | LE, | Glycyrrhizin ameliorates colorectal cancer progression by regulating NHEJ pathway through inhibiting HMGB1-induced DNA damage response |
| - | vitro+vivo, | CRC, | NA |
| 8282- | LE, | Glycyrrhizic Acid Inhibits Proliferation of Gastric Cancer Cells by Inducing Cell Cycle Arrest and Apoptosis |
| - | in-vitro, | GC, | MGC803 | - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 |
| 8277- | LE, | Oncopreventive and oncotherapeutic potential of licorice triterpenoid compound glycyrrhizin and its derivatives: Molecular insights |
| - | Review, | Var, | NA |
| 8279- | LE, | 18β-Glycyrrhetinic Acid Has Anti-Cancer Effects via Inducing Apoptosis and G2/M Cell Cycle Arrest, and Inhibiting Migration of A549 Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H460 |
| 8135- | LF, | Lactoferrin-A Regulator of Iron Homeostasis and Its Implications in Cancer |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 8144- | LF, | A pilot study on the effect of lactoferrin on Alzheimer's disease pathological sequelae: Impact of the p-Akt/PTEN pathway |
| - | Human, | AD, | NA |
| 8199- | LGE, | Citral is a new inducer of caspase-3 in tumor cell lines |
| - | in-vitro, | Var, | NA |
| 8195- | LGE, | In Vivo Anti-Tumor Effects of Citral on 4T1 Breast Cancer Cells via Induction of Apoptosis and Downregulation of Aldehyde Dehydrogenase Activity |
| - | vitro+vivo, | BC, | 4T1 |
| 8187- | LGE, | Modulation of oxidative stress and subsequent induction of apoptosis and endoplasmic reticulum stress allows citral to decrease cancer cell proliferation |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | Ovarian, | OVCAR-3 | - | in-vitro, | Ovarian, | SKOV3 |
| 8183- | LGE, | Antiproliferative and apoptosis inducing effects of citral via p53 and ROS-induced mitochondrial-mediated apoptosis in human colorectal HCT116 and HT29 cell lines |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 8330- | LIN, | SIRT3-SOD2-ROS pathway is involved in linalool-induced glioma cell apoptotic death |
| - | in-vitro, | GBM, | U87MG |
| 8323- | LIN, | doxoR, | Efficacy of Combination Therapy with Linalool and Doxorubicin Encapsulated by Liposomes as a Two-in-One Hybrid Carrier System for Epithelial Ovarian Carcinoma |
| - | vitro+vivo, | Ovarian, | NA |
| 8320- | LIN, | Ameliorative Effect of Linalool in Cisplatin-Induced Nephrotoxicity: The Role of HMGB1/TLR4/NF-κB and Nrf2/HO1 Pathways |
| - | in-vivo, | Nor, | NA |
| 8317- | LIN, | Linalool induces cell cycle arrest and apoptosis in HepG2 cells through oxidative stress generation and modulation of Ras/MAPK and Akt/mTOR pathways |
| - | in-vitro, | Liver, | HepG2 |
| 6483- | LIN, | Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma |
| - | in-vitro, | Ovarian, | A2780S |
| 8382- | LT, | Luteolin as a dietary flavonoid for brain health: modulating neuroinflammation and cognitive decline in neurodegenerative disorders |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 8379- | LT, | Luteolin and neuroinflammation: a multi-target therapeutic strategy for central nervous system disorders |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 8377- | LT, | Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases |
| - | Review, | Asthma, | NA |
| 8384- | LT, | Current situation and research progress of luteolin in the treatment of gastrointestinal malignant tumors |
| - | Review, | GC, | NA |
| 8386- | LT, | Luteolin induces apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia cell by regulating the PI3K/AKT signaling pathway |
| - | in-vitro, | ALL, | SUP-B15 |
| 8389- | LT, | Luteolin-Manganese Nanozyme Induces Apoptosis and Ferroptosis for Enhanced Cancer Therapy |
| - | in-vitro, | Var, | NA |
| 8390- | LT, | Luteolin in Inflammatory Bowel Disease and Colorectal Cancer: A Disease Continuum Perspective |
| - | Review, | IBD, | NA | - | Review, | CRC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:42 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid